Latest news with #DAAP
Yahoo
18-07-2025
- Business
- Yahoo
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?
OptimizeRx OPRX delivered an encouraging first-quarter 2025, with revenues rising 11% year over year to $21.9 million and adjusted EBITDA reaching $1.5 million — a significant year-over-year turnaround. Despite its seasonally weakest quarter, OPRX is seeing momentum in its core platform, anchored by DAAP and advanced micro-neighborhood targeting. The company's strength lies in its broad reach across point-of-care networks and its ability to integrate direct-to-consumer (DTC) and HCP-facing campaigns. CEO Steve Silvestro emphasized that OPRX is being increasingly viewed as a strategic commercialization partner, especially as pharma spending gets more focused and selective. Their platform's ROI — claimed at over 10:1 — and a 25% script lift in six months underscore its value proposition in a tightening market. Also, more than 80% of its 2025 revenues are already contracted, and the company has begun shifting toward a subscription-based model, with early traction in data-as-a-service offerings. This could bring margin stability and predictability, which are key for long-term value creation. Though gross margin dipped slightly due to a higher mix of managed services, the company is confident about its ability sustain margins in the 60% range while expanding high-margin data solutions. OptimizeRx also addressed concerns about regulatory pressures and pharma budget volatility, stating it hasn't seen meaningful headwinds yet. Rather, there's greater client focus on cost-effective digital solutions, which could be a tailwind for OPRX. In a fiercely competitive digital health space where giants like Veeva are evolving rapidly, OPRX's integration of scalable omnichannel tools and data-driven insights may provide it with a durable edge if it continues to execute with discipline and agility. The challenge lies in scaling subscriptions while maintaining innovation to avoid margin pressures and defend its niche in a shifting digital engagement landscape. Tools From Peers Omnicell OMCL is reinforcing its digital health strategy through the Intelligence-Enabled Pharmacy vision. The company is scaling its OmniSphere platform — a cloud-based, AI-powered solution that offers predictive analytics and real-time medication inventory management. Despite near-term macroeconomic challenges and a pause in large-scale capex projects, Omnicell remains committed to automating and digitally transforming medication management workflows across hospitals and health systems. OMCL's Advanced Services suite further integrates automation, analytics, and remote pharmacy services, aimed at optimizing clinical and financial outcomes for healthcare providers. These innovations position Omnicell as a strategic enabler of smart, data-driven pharmacy operations. Teladoc Health TDOC is doubling down on digital mental health with its BetterHelp platform and recent acquisition of UpLift, an in-network virtual mental health provider. This move enables Teladoc to offer covered-benefits therapy options to users, improving conversion rates and reducing out-of-pocket costs. UpLift's network of more than 1,500 licensed professionals complements BetterHelp's reach of 35,000 therapists, supporting therapy, psychiatry and medication management. Teladoc is also investing in AI-enabled clinical documentation tools and its Prism care delivery platform, which enhances integration across the virtual care ecosystem. These steps underline its ambition to deliver scalable, tech-driven behavioral and chronic care solutions globally. OPRX's Price Performance, Valuation and Estimates Shares of OptimizeRx have surged 187.9% year to date compared with the industry's growth of 18%. Image Source: Zacks Investment Research OPRX's forward 12-month P/S of 2.33X is lower than the industry's average of 8.86X, and also lower than its five-year median of 3.57X. However, it carries a Value Scoreof F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for OPRX's 2025 earnings per share suggests a 63.6% improvement from the 2024 level. Image Source: Zacks Investment Research OptimizeRx stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicell, Inc. (OMCL) : Free Stock Analysis Report OptimizeRx Corp. (OPRX) : Free Stock Analysis Report Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Express Tribune
23-06-2025
- Health
- Express Tribune
Conference urges safer, standardised aesthetic practices
While looking beautiful is every individual's right, aesthetic procedures should only be performed by trained and registered professionals, stressed President of the Dermatology and Aesthetic Association of Pakistan (DAAP), Dr Bilal Shah, at the DAAPCon 2025 conference. The moot, held under DAAP's auspices, stressed the need to standardise and regulate aesthetic and beauty practices in the country, highlighting the growing trend of receiving cosmetic treatments, as well as the consequences of lack of knowledge and unstandardised aesthetic practices in Pakistan. Many dermatologists and aesthetic physicians participated in the event, while pharmaceutical companies also set up stalls. Dr Bilal Shah stated that undergoing aesthetic procedures at the hands of untrained individuals is not only dangerous but often leads to permanent damage, urging the Pakistan Medical and Dental Council (PMDC), and relevant regulatory bodies, to take action against substandard clinics and unqualified individuals. Celebrity dermatologist and organising committee member Dr Zara Shah stated that actresses and models commonly face pressure to lose weight or get nose reshaping, even though they often do not need these procedures. She explained that young girls also get expensive treatments like lip fillers and nose jobs, but due to a lack of knowledge, end up damaging their faces. Dr Zara further noted that aesthetic procedures start at around Rs5,000 and can go up to Rs250,000-300,000 for advanced treatments. She explained that laser treatments are used to remove unwanted facial hair, eliminate melasma (dark patches), and enhance the overall appearance of the face, with many girls aspiring to achieve 'Korean glass skin', although it is important to understand the genetic differences between populations. Additionally, she noted that exosome therapy is now being used to enhance beauty and maintain youthful skin, explaining that exosomes are natural particles in the body that help repair and regenerate skin. This therapy treats issues like pigmentation, wrinkles, acne, and hair loss, providing a collagen boost to the skin without surgery, making it look younger and fresher. The conference offered the opportunity to learn about the latest aesthetic technologies, devices, and the experiences of medical professionals, with the aim of delivering better, safer, and more standardised, aesthetic services to Pakistani society.
Yahoo
28-05-2025
- Business
- Yahoo
FedEx and ShopRunner Voluntarily Comply with BBB National Programs' Digital Privacy Watchdog Consumer Data Privacy Standards
The FedEx Corporation has collaborated with BBB National Programs' Digital Advertising Accountability Program (DAAP) to enhance its privacy disclosures on FedEx mobile applications, and ShopRunner mobile applications to follow the Digital Advertising Alliance's (DAA) Self-Regulatory Principles for Online Behavioral Advertising (OBA). McLean, VA, May 28, 2025 (GLOBE NEWSWIRE) -- The FedEx Corporation has collaborated with BBB National Programs' Digital Advertising Accountability Program (DAAP) to enhance its privacy disclosures on FedEx mobile applications, and ShopRunner mobile applications to follow the Digital Advertising Alliance's (DAA) Self-Regulatory Principles for Online Behavioral Advertising (OBA). FedEx is a company best known for its transportation, e-commerce, and shipping services. FedEx publishes the website, as well as the iOS and Android FedEx mobile applications. ShopRunner is an e-commerce platform acquired by FedEx in 2020 that connects millions of consumers to over 100 brands. ShopRunner publishes the website, as well as the iOS and Android ShopRunner mobile applications. DAA's Self-Regulatory Principles for OBA apply to entities engaged in interest-based advertising (IBA) to help ensure they adhere to consumer data privacy best practices. The OBA Principles were developed by leading industry associations to apply consumer-friendly standards to online behavioral advertising across the internet. DAAP monitors the digital marketplace for compliance with the DAA's OBA Principles. The DAA Principles require websites and apps to provide a distinct link (known as enhanced notice) taking users directly to a notice that explains the IBA occurring on the site, provides a method for users to opt out of third-party IBA, and states that the company adheres to the DAA Principles. When DAAP examined the FedEx website, the site had a footer labeled 'Privacy & Security' that directed users to the top of FedEx's privacy policy, which contained information about IBA scattered in several sections. Similarly, the ShopRunner website had a footer link labeled 'Policies' that directed users to ShopRunner's privacy policy, which likewise had scattered information about its IBA practices. Neither site had the separate, distinct, and clearly labeled link directing users to an IBA disclosure with a method to opt out of third-party IBA or the required statement of the company's adherence to the DAA Principles. On the FedEx and ShopRunner mobile applications, DAAP identified the same issue as with the websites. Data collection by third-party companies known to engage in IBA was found, but enhanced notice was not present. In response to DAAP's inquiry, FedEx and ShopRunner each conducted a detailed review of their compliance with DAA Principles and worked to find comprehensive solutions to each issue. FedEx and ShopRunner collaborated with DAAP on the following: Enhanced Notice IBA Data Collection FedEx added a website footer link titled 'Ad Choices' and updated its Trust Center to prominently display the following sentence: 'Learn more about Interest-based Advertising and your Ad Choices.' Each now links users to Section 7 of the privacy policy, titled 'Does FedEx use Cookies and Interest-Based Advertising?' and complies with the DAA Principles. ShopRunner added a website footer link titled 'Interest based ads' that takes users directly to the IBA section of the privacy policy, in compliance with DAA Data Cross-App Data Collection Compliance FedEx made significant changes to ensure IBA disclosures were accessible to users in places prescribed by the DAA's Mobile Guidance, including adding privacy policy links that direct users to the top of FedEx's Trust Center to FedEx's iOS and Android app store listings. ShopRunner made considerable changes to its mobile apps to ensure IBA disclosures were accessible to users in places prescribed by the DAA's Mobile Guidance, including adding privacy policy links that direct users to the IBA section of ShopRunner's privacy policy webpage to ShopRunner's iOS and Android app store listings. Strengthening IBA Sections of FedEx and ShopRunner's Privacy Policies FedEx and ShopRunner worked with DAAP to update their respective privacy policy sections on IBA, so that any scattered references to IBA across the privacy policy are now consolidated under the same section, making it easier for consumers to read and understand. The sections now include all elements of DAA enhanced notice together, namely 1) a description of IBA practices, including how data can be shared with third parties for IBA, as well as web tracking technologies used on the respective company's digital properties, (2) a link to, and description of, industry-developed IBA opt-out tools, and (3) a statement of adherence to the DAA Principles. In their combined company statement, FedEx and ShopRunner stated they 'are committed to delivering a seamless online experience, grounded in the core principles of privacy, transparency, and customer trust.' All BBB National Programs case decision summaries can be found in the case decision library. For the full text of DAAP decisions, visit the DAAP Decisions and Guidance webpage. About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit About the Digital Advertising Accountability Program: The Digital Advertising Accountability Program (DAAP), a division of BBB National Programs, was developed by the Digital Advertising Alliance (DAA) to enforce industry self-regulation principles for data privacy in online and mobile advertising, holding companies accountable to the DAA's Privacy Principles. DAAP provides guidance to companies looking to comply with industry principles and responds to complaints filed by consumers about online privacy. CONTACT: Name: Jennie Rosenberg Email: jrosenberg@ Job Title: Media RelationsError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
11-03-2025
- Business
- Associated Press
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the 'Company') (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today confirmed that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders. The OptimizeRx Board of Directors will make its formal recommendation regarding director nominations in the Company's definitive proxy statement which will be filed with the Securities and Exchange Commission and mailed to stockholders eligible to vote at the Company's 2025 Annual Meeting of Stockholders, which has not yet been scheduled. About OptimizeRx OptimizeRx is a leading healthcare technology company that's redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world's leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all. Important Cautions Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates', 'believes', 'estimates', 'expects', 'forecasts', 'intends', 'plans', 'projects', 'targets', 'designed', 'could', 'may', 'should', 'will' or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. Important Additional Information And Where To Find It OptimIzeRx Corporation (the 'Company') plans to file proxy materials with the U.S. Securities and Exchange Commission (the 'SEC') in connection with the solicitation of proxies for the Company's 2025 annual meeting of stockholders (the '2025 Annual Meeting'). Prior to the 2025 Annual Meeting, the Company will file a definitive proxy statement (the 'Proxy Statement') together with a WHITE proxy card. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders will be able to obtain, free of charge, copies of the Proxy Statement, any amendments or supplements thereto and any other documents (including the WHITE proxy card) when filed by the Company with the SEC at the SEC's website ( or at the Company's website at or by contacting Andy D'Silva, SVP - Finance, by email at [email protected] or by mail at OptimizeRx Corporation, 260 Charles Street, Suite 302, Waltham, MA 02453. Certain Information Regarding Participants The Company, its directors, certain of its executive officers, and other employees may be deemed to be 'participants' (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from stockholders in connection with the 2025 Annual Meeting. Additional information regarding the identity of these participants and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement and other materials to be filed with the SEC in connection with the 2025 Annual Meeting. Information relating to the foregoing can also be found in the Company's definitive proxy statement for its 2024 annual meeting of stockholders, filed with the SEC on April 29, 2024. To the extent holdings of such participants in the Company's securities have changed since the amounts described in the 2024 proxy statement, such changes have been reflected in the following Statements of Change in Beneficial Ownership on Form 4 filed with the SEC with respect to the Company: Form 4, filed by Stephen L. Silvestro on March 4, 2025; Form 4, filed by Stephen L. Silvestro on February 20, 2025; Form 4, filed by Edward Stelmakh on February 20, 2025; Form 4, filed by Cathy Klema on February 4, 2025; Form 4/A, filed by Edward Stelmakh on December 27, 2024; Form 4, filed by Stephen L. Silvestro on December 27, 2024; Form 4, filed by Edward Stelmakh on December 27, 2024; Form 4, filed by Edward Stelmakh on December 20, 2024; Form 4, filed by Stephen L. Silvestro on December 20, 2024; Form 4, filed by Edward Stelmakh on October 15, 2024; Form 4, filed by Stephen L. Silvestro on October 7, 2024; Form 4, filed by Edward Stelmakh on October 7, 2024; Form 4, filed by Gregory D. Wasson on June 11, 2024; Form 4, filed by Cathy Klema on June 11, 2024; Form 4, filed by Ellen O'Connor Vos on June 11, 2024; Form 4, filed by James Paul Lang on June 11, 2024; Form 4, filed by Patrick Spangler on June 11, 2024; Form 4/A, filed by Stephen L. Silvestro on May 6, 2024; Form 4, filed by Stephen L. Silvestro on May 6, 2024; and Form 4/A, filed by Stephen L. Silvestro on May 6, 2024. These filings can be found at the SEC's website at More detailed and updated information regarding the identity of participants in the solicitation, and their direct or indirect interests (by security holdings or otherwise), will be set forth in the Proxy Statement and other materials to be filed with the SEC. These documents can be obtained free of charge from the sources indicated above. OptimizeRx Contact Investor Relations Contact Sandya von der Weid LifeSci Advisors, LLC
Yahoo
11-03-2025
- Business
- Yahoo
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
No Stockholder Action Required at this Time WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the 'Company') (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today confirmed that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders. The OptimizeRx Board of Directors will make its formal recommendation regarding director nominations in the Company's definitive proxy statement which will be filed with the Securities and Exchange Commission and mailed to stockholders eligible to vote at the Company's 2025 Annual Meeting of Stockholders, which has not yet been scheduled. About OptimizeRx OptimizeRx is a leading healthcare technology company that's redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world's leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all. Important Cautions Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates', 'believes', 'estimates', 'expects', 'forecasts', 'intends', 'plans', 'projects', 'targets', 'designed', 'could', 'may', 'should', 'will' or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. Important Additional Information And Where To Find It OptimIzeRx Corporation (the 'Company') plans to file proxy materials with the U.S. Securities and Exchange Commission (the 'SEC') in connection with the solicitation of proxies for the Company's 2025 annual meeting of stockholders (the '2025 Annual Meeting'). Prior to the 2025 Annual Meeting, the Company will file a definitive proxy statement (the 'Proxy Statement') together with a WHITE proxy card. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders will be able to obtain, free of charge, copies of the Proxy Statement, any amendments or supplements thereto and any other documents (including the WHITE proxy card) when filed by the Company with the SEC at the SEC's website ( or at the Company's website at or by contacting Andy D'Silva, SVP - Finance, by email at adsilva@ or by mail at OptimizeRx Corporation, 260 Charles Street, Suite 302, Waltham, MA 02453. Certain Information Regarding Participants The Company, its directors, certain of its executive officers, and other employees may be deemed to be 'participants' (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from stockholders in connection with the 2025 Annual Meeting. Additional information regarding the identity of these participants and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement and other materials to be filed with the SEC in connection with the 2025 Annual Meeting. Information relating to the foregoing can also be found in the Company's definitive proxy statement for its 2024 annual meeting of stockholders, filed with the SEC on April 29, 2024. To the extent holdings of such participants in the Company's securities have changed since the amounts described in the 2024 proxy statement, such changes have been reflected in the following Statements of Change in Beneficial Ownership on Form 4 filed with the SEC with respect to the Company: Form 4, filed by Stephen L. Silvestro on March 4, 2025; Form 4, filed by Stephen L. Silvestro on February 20, 2025; Form 4, filed by Edward Stelmakh on February 20, 2025; Form 4, filed by Cathy Klema on February 4, 2025; Form 4/A, filed by Edward Stelmakh on December 27, 2024; Form 4, filed by Stephen L. Silvestro on December 27, 2024; Form 4, filed by Edward Stelmakh on December 27, 2024; Form 4, filed by Edward Stelmakh on December 20, 2024; Form 4, filed by Stephen L. Silvestro on December 20, 2024; Form 4, filed by Edward Stelmakh on October 15, 2024; Form 4, filed by Stephen L. Silvestro on October 7, 2024; Form 4, filed by Edward Stelmakh on October 7, 2024; Form 4, filed by Gregory D. Wasson on June 11, 2024; Form 4, filed by Cathy Klema on June 11, 2024; Form 4, filed by Ellen O'Connor Vos on June 11, 2024; Form 4, filed by James Paul Lang on June 11, 2024; Form 4, filed by Patrick Spangler on June 11, 2024; Form 4/A, filed by Stephen L. Silvestro on May 6, 2024; Form 4, filed by Stephen L. Silvestro on May 6, 2024; and Form 4/A, filed by Stephen L. Silvestro on May 6, 2024. These filings can be found at the SEC's website at More detailed and updated information regarding the identity of participants in the solicitation, and their direct or indirect interests (by security holdings or otherwise), will be set forth in the Proxy Statement and other materials to be filed with the SEC. These documents can be obtained free of charge from the sources indicated above. OptimizeRx Contact Andy D'Silva, SVP Corporate Finance adsilva@ Investor Relations ContactSandya von der WeidLifeSci Advisors, LLCsvonderweid@ in to access your portfolio
